China trial shows gum tissue stem cells help 55% of lifetime diabetes patients
A randomised phase 1 clinical trial conducted by scientists and doctors from Shanghai and Guangzhou has achieved encouraging results in the treatment of Type 1 diabetes using stem cells extracted from the mouth’s gum tissue. More than half of those who received the treatment showed varying degrees of improvement, while one subject was able to discontinue exogenous insulin therapy completely, the…
Scientists and doctors from Shanghai and Guangzhou conducted a randomized phase 1 clinical trial that demonstrated promising results in treating Type 1 diabetes using stem cells from gum tissue. The study, published on September 30 in the medical journal Signal Transduction and Targeted Therapy, involved 18 patients with Type 1 diabetes who received either gingival mesenchymal stem cells (GMSC) or a placebo.
After receiving four treatments over 48 weeks, 55.6% of those receiving GMSC showed varying degrees of improvement in residual beta-cell function, and one patient was able to discontinue exogenous insulin therapy completely. The therapy is considered promising for developing immune-targeted treatments for Type 1 diabetes, with further large-scale studies needed to validate the findings.
Written by urgent.news from South China Morning Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
